Adverse Effects of Pharmacotherapy in Children with Enuresis: A Single Centre Experience

To assess side effects of MELT monotherapy and MELT in association with oxybutynin in children suffering from nocturnal enuresis (NE). We enrolled 340 enuretic children admitted to our Pediatric Service, Campus Bio-Medico University of Rome, from April 2014 to April 2018; 23 children were excluded. The research was structured in 2 steps. During step 1, a patient’s medical history was carefully collected and physical assessment was performed. During step 2, after 3-month treatment period with MELT (Minirin/dDAVP®) at the dose of 120 mcg a day or MELT plus oxybutynin (Ditropan®), voiding calendar, adherence to treatment and any side effects were examined. The study was conducted in accordance with the Helsinki Declaration. Among 317 patients enrolled in the study, 18 male and 8 female (n=26; 26/317: 8.2%) children, with a mean age 10.86 ± 2.42 years, referred side effects: 13 cases (n=13, 13/26: 50%) treated with MELT monotherapy, 11 cases (n=11, 11/26: 42.3%) treated with MELT plus oxybutynin, 2 cases (n=2, 2/26: 7.7%) who received only oxybutynin. In our research, higher bioavailability of MELT guaranteed lower frequency of adverse effects with a spontaneous and rapid resolution. Several studies demonstrate that dDAVP is an effective and safe drug for NE and MELT formulation is actually considered for first-line therapy of NE, although further research is needed to endorse the observations of the authors.

Download Full-text

PB2138 LIGHT CHAIN (AL) AMYLOIDOSIS: A SINGLE CENTRE EXPERIENCE AND THE EFFECTIVENESS OF BORTEZOMIB BASED THERAPY AS FIRST LINE THERAPY

HemaSphere ◽

10.1097/01.hs9.0000567036.31064.32 ◽

2019 ◽

Vol 3 (S1) ◽

pp. 962-963

Author(s):

H. Ngu ◽

D. Simpson ◽

M. Hanna ◽

R. Henderson ◽

E. Merriman ◽

...

Keyword(s):

Light Chain ◽

Al Amyloidosis ◽

First Line ◽

Single Centre ◽

First Line Therapy ◽

Line Therapy ◽

Single Centre Experience

Download Full-text

Catheter ablation of atrial fibrillation as first-line therapy--a single-centre experience

EP Europace ◽

10.1093/europace/eur065 ◽

2011 ◽

Vol 13 (5) ◽

pp. 646-653 ◽

Cited By ~ 23

Author(s):

H. Tanner ◽

K. Makowski ◽

L. Roten ◽

J. Seiler ◽

N. Schwick ◽

...

Keyword(s):

Atrial Fibrillation ◽

Catheter Ablation ◽

First Line ◽

Single Centre ◽

First Line Therapy ◽

Line Therapy ◽

Single Centre Experience

Download Full-text

EFFICACY OF MODIFIED BISMUTH QUADRUPLE THERAPY (RBMA) AS FIRST-LINE THERAPY FOR ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH CHRONIC GASTRITIS

Journal of Medicine and Pharmacy ◽

10.34071/jmp.2019.2.5 ◽

2019 ◽

pp. 28-32

Author(s):

Van Huy Tran

Keyword(s):

Helicobacter Pylori ◽

Adverse Effects ◽

Chronic Gastritis ◽

Eradication Rate ◽

High Rate ◽

First Line ◽

Helicobacter Pylori Eradication ◽

Quadruple Therapy ◽

First Line Therapy ◽

Line Therapy

Background and aims: Efficacy with substitution of tetracycline with amoxicillin, an antibiotics having a very low resistance rate and a high tolerability, in bismuth quadruple therapy (BQT) have not been studied in Vietnam. Our study aimed to evaluate the efficacy and tolerability of modified BQT vs. standard BQT for first-line Helicobacter pylori eradication. Patients and methods: This is a randomized, prospective study. 120 patients with H.pylori positive-chronic gastritis were randomly divided into two groups. The RBMA group containing rabeprazole 20 mg, bismuth subsalicylic 524mg, metronidazole 500mg, amoxicillin 1000mg, all 2 times a day, for 14 days. The RBMT group received rabeprazole, bismuth subsalicylic, metronidazole and tetracycline. Evaluation for compliance and drug-related side effects were evaluated at the end of two weeks. 4-6 weeks after the end of treatment, the H.pylori eradication rate was determined by the C13urease breath test. Results: Eradication rate was not statistically significative different between the RBMA and the RBMT: 91.2%; 95% confidence interval, 78.2% - 96.7%) vs. 90%; 95% CI, 81.6% - 96.3%) by per-protocol analysis (p = 0.42) and 86.7% (95%CI, 75.84% - 93.09%) vs. 75% (95%CI, 62.1% - 85.3%) by intention-to-treat analysis (ITT, p = 0.06). Adverse effects were significant higher in the RBMT group than in the RBMA group (48.3% vs. 26.7%; p = 0.071) and rate of good compliance was significantly higher in RBMA group than in RBMT group (p < 0.05). Conclusion: The modified BQT including rabeprazole, bismuth, metronidazole and amoxicillin achieved a fairly high rate of H.pylori infection eradication with a higher compliance and lower rate of adverse effects compared to the BQT in patients with chronic gastritis. Further studies need to conduct to confirm this new regimens as a first-line therapy in our country. Key words: Modified bismuth quadruple therapy, BQT, Helicobacter pylori eradication

Download Full-text

Comparison of First-line Pazopanib and Sunitinib in Metastatic Renal Cell Carcinoma: Experiences of the Urologic Cancer Centre for Research and Innovation

10.21203/rs.2.18147/v1 ◽

2019 ◽

Author(s):

Emily C.L. Wong ◽

Camilla Tajzler ◽

Gaurav Vasisth ◽

Amanda Zhu ◽

Mathilda Chow ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Side Effects ◽

Cell Carcinoma ◽

Disease Progression ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Significant Difference

Abstract Background: Sunitinib and pazopanib are orally-administered tyrosine kinase receptor inhibitors (TKIs) approved as first-line therapy for the treatment of metastatic renal cell carcinoma (mRCC). The IMDC criteria are a predictive prognostic model for patients with mRCC when stratified into three prognosis groups: favourable, intermediate and poor. We retrospectively compared the efficacy and safety of sunitinib and pazopanib as first-line therapy for patients with mRCC in our single institution database. Methods: Retrospective analysis was done to compare progression-free survival (PFS) and side effects of sunitinib and pazopanib as first-line therapy in patients with mRCC. Patients were stratified into prognosis groups according to IMDC criteria. Disease assessment was performed on measurable aspects of disease based on computed tomography or magnetic resonance imaging reports. Survival analysis was performed using the Kaplan-Meier method and Cox regression, with disease progression as the endpoint.Results: Data was obtained from 228 patients with mRCC who were treated with either pazopanib (n=57) or sunitinib (n=171). No significant difference in PFS was found between sunitinib and pazopanib (HR for disease progression or all-cause death, 1.10; 95%CI: 0.76-1.57, p=0.62). Median PFS time for patients receiving sunitinib was 9.4 months and for pazopanib, 8.5 months. Median PFS for patients with intermediate-risk disease was similar between groups (9.4 months vs. 9.2 months, respectively, p=0.93). However, patients treated with sunitinib experienced a greater number of side effects compared to pazopanib. Conclusions: Sunitinib and pazopanib are similarly efficacious as first-line therapy for mRCC. However, adverse events are lower with pazopanib.

Download Full-text

Rituximab as first-line therapy for acquired haemophilia A: a single-centre 10-year experience

Haemophilia ◽

10.1111/hae.12973 ◽

2016 ◽

Vol 22 (4) ◽

pp. e338-e341 ◽

Cited By ~ 4

Author(s):

B. Rossi ◽

P. Blanche ◽

V. Roussel-Robert ◽

A. Berezné ◽

S. Combe ◽

...

Keyword(s):

Haemophilia A ◽

First Line ◽

Single Centre ◽

Acquired Haemophilia ◽

First Line Therapy ◽

Line Therapy

Download Full-text

A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer - CONKO 003

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.4517 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 4517-4517 ◽

Cited By ~ 8

Author(s):

H. Riess ◽

U. Pelzer ◽

J. Stieler ◽

I. Schwaner ◽

G. Heil ◽

...

Keyword(s):

Pancreatic Cancer ◽

Side Effects ◽

Disease Progression ◽

Advanced Pancreatic Cancer ◽

Phase Iii ◽

Second Line ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

The Impact

4517 Objective: For nearly ten years gemcitabine (G) was standard first line therapy for patients (pts) with advanced pancreatic cancer (APC). There is no consensus about second line therapy after disease progression while receiving G, but 5-FU-based regimens are considered. Results about randomized second line studies in APC are very rare. Our phase II study (ASCO 2002) showed activity of the OFF (oxaliplatin/folinic Acid (FA)/5-fluorouracil (FU) [24h] ) regimen in 23 pts. To examine the impact and the side effects of oxaliplatin we initiated a multicenter phase III study to compare OFF and FF in pts with G refractory APC. Methods: Pts with CT/ MRT confirmed failure with G in first line therapy, Karnofsky Performance Status (KPS) >60%, controlled pain, adequate hematological, renal and liver functions were eligible. Pts were stratified according to duration of first line therapy, KPS and tumor stage. We randomized pts to outpatient treatment with FF (FU 2g/m2 (24h)/ FA 200 mg/m2 (30min) on d1, d8, d15 and d22) or OFF (FF+Oxaliplatin 85mg/m2, d8, d22). In both arms the next cycle started on day 43. Pts were followed with regular staging every 3 months or at any signs of disease progression. Results: Until now we randomized 161 of 165 (planned) pts between 02/2004 and 01/2007. So we expect to present first results (side effects, progression free survival, overall survival) at the meeting. No significant financial relationships to disclose.

Download Full-text

Complementary drugs—herbs, vitamins, and dietary supplements for pain and symptom management

Oxford Textbook of Paediatric Pain ◽

10.1093/med/9780199642656.003.0059 ◽

2013 ◽

pp. 613-622

Author(s):

Joy A. Weydert

Keyword(s):

Side Effects ◽

Dietary Supplements ◽

Symptom Management ◽

Nutritional Supplements ◽

First Line ◽

Pharmacological Agents ◽

First Line Therapy ◽

Line Therapy

Because of the interest of patients and physicians, there has been increasing research into the use of botanical agents, nutritional supplements, and diet as a means to manage pain. Pharmacological agents typically are chosen as first-line therapy for pain and symptom management; however, for some patients these agents may not work well long term or have side effects that are not tolerated. Other patients may prefer non-pharmacological therapies. Most clinicians are not trained or may not be comfortable recommending these complementary agents.

Download Full-text